- Home
- AAOI vs PRAX Comparison
AAOI vs PRAX Comparison
Compare AAOI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAOI
- PRAX
- Stock Information
- Founded
- AAOI 1997
- PRAX 2015
- Country
- AAOI United States
- PRAX United States
- Employees
- AAOI N/A
- PRAX N/A
- Industry
- AAOI Semiconductors
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- AAOI Technology
- PRAX Health Care
- Exchange
- AAOI Nasdaq
- PRAX Nasdaq
- Market Cap
- AAOI 950.4M
- PRAX 950.8M
- IPO Year
- AAOI 2013
- PRAX 2020
- Fundamental
- Price
- AAOI $29.47
- PRAX $44.03
- Analyst Decision
- AAOI Buy
- PRAX Strong Buy
- Analyst Count
- AAOI 6
- PRAX 9
- Target Price
- AAOI $28.40
- PRAX $94.44
- AVG Volume (30 Days)
- AAOI 5.1M
- PRAX 383.5K
- Earning Date
- AAOI 11-06-2025
- PRAX 11-05-2025
- Dividend Yield
- AAOI N/A
- PRAX N/A
- EPS Growth
- AAOI N/A
- PRAX N/A
- EPS
- AAOI N/A
- PRAX N/A
- Revenue
- AAOI $368,233,000.00
- PRAX $7,765,000.00
- Revenue This Year
- AAOI $91.13
- PRAX N/A
- Revenue Next Year
- AAOI $55.88
- PRAX $22.22
- P/E Ratio
- AAOI N/A
- PRAX N/A
- Revenue Growth
- AAOI 77.94
- PRAX 338.45
- 52 Week Low
- AAOI $9.71
- PRAX $26.70
- 52 Week High
- AAOI $44.50
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- AAOI 64.13
- PRAX 48.77
- Support Level
- AAOI $27.30
- PRAX $37.25
- Resistance Level
- AAOI $29.80
- PRAX $40.69
- Average True Range (ATR)
- AAOI 2.02
- PRAX 2.54
- MACD
- AAOI 0.62
- PRAX -0.03
- Stochastic Oscillator
- AAOI 92.82
- PRAX 61.04
About AAOI Applied Optoelectronics Inc.
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.